Health Care • Biotechnology: Pharmaceutical Preparations
$53.67 ▲ +1.87
(+3.61%)
MKT CAP: $1.53B • VOL: 369.5K
52W L $14 52W H $66
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$45
MEDIAN
$60
MEAN
$61
HIGH
$73
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ETON TAPE
ETON // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $64.94 | $61.72 | 2025-02-14 | $48.84 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $67.62 | $63.33 | 2025-02-06 | $50.45 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $61.18 | $59.04 | 2025-01-29 | $51.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $54.74 | — | 2025-01-17 | $52.60 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $47.23 | $50.99 | 2025-01-09 | $47.77 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $63.87 | $55.82 | 2024-12-18 | $46.69 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $52.06 | $54.21 | 2024-12-04 | $49.91 | -4.3% | 48% | C |